PMID- 37091188
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230425
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, 
      and nilotinib for chronic myeloid leukemia: From clinical trials to real-life 
      settings.
PG  - 1146108
LID - 10.3389/fonc.2023.1146108 [doi]
LID - 1146108
AB  - With the advent of tyrosine kinase inhibitors (TKIs), the treatment prospects of 
      chronic myeloid leukemia (CML) have changed markedly. This innovation can 
      lengthen the long-term survival of patients suffering from CML. However, 
      long-term exposure to TKIs is accompanied by various adverse events (AEs). The 
      latter affect the quality of life and compliance of patients with CML, and may 
      lead to serious disease progression (and even death). Recently, increasing 
      numbers of patients with CML have begun to pursue a dose optimization strategy. 
      Dose optimization may be considered at all stages of the entire treatment, which 
      includes dose reduction and discontinuation of TKIs therapy. In general, 
      reduction of the TKI dose is considered to be an important measure to reduce AEs 
      and improve quality of life on the premise of maintaining molecular responses. 
      Furthermore, discontinuation of TKIs therapy has been demonstrated to be feasible 
      and safe for about half of patients with a stable optimal response and a longer 
      duration of TKI treatment. This review focuses mainly on the latest research of 
      dose optimization of imatinib, dasatinib, and nilotinib in CML clinical trials 
      and real-life settings. We consider dose reduction in newly diagnosed patients, 
      or in optimal response, or for improving AEs, either as a prelude to 
      treatment-free remission (TFR) or as maintenance therapy in those patients unable 
      to discontinue TKIs therapy. In addition, we also focus on discontinuation of 
      TKIs therapy and second attempts to achieve TFR.
CI  - Copyright (c) 2023 Cheng, Li, Cui, Hong, Li and Zhang.
FAU - Cheng, Fang
AU  - Cheng F
AD  - Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
AD  - Hubei Province Clinical Research Center for Precision Medicine for Critical 
      Illness, Wuhan, China.
AD  - Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji 
      Medical College, Huazhong University of Science and Technology, Wuhan, China.
FAU - Li, Qiang
AU  - Li Q
AD  - Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
AD  - Hubei Province Clinical Research Center for Precision Medicine for Critical 
      Illness, Wuhan, China.
FAU - Cui, Zheng
AU  - Cui Z
AD  - Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
AD  - Hubei Province Clinical Research Center for Precision Medicine for Critical 
      Illness, Wuhan, China.
FAU - Hong, Mei
AU  - Hong M
AD  - Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji 
      Medical College, Huazhong University of Science and Technology, Wuhan, China.
FAU - Li, Weiming
AU  - Li W
AD  - Department of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Zhang, Yu
AU  - Zhang Y
AD  - Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
AD  - Hubei Province Clinical Research Center for Precision Medicine for Critical 
      Illness, Wuhan, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230405
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10113500
OTO - NOTNLM
OT  - chronic myeloid leukemia
OT  - dose optimization
OT  - dose reduction
OT  - treatment-free remission
OT  - tyrosine kinase inhibitors
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/04/24 06:41
MHDA- 2023/04/24 06:42
PMCR- 2023/01/01
CRDT- 2023/04/24 03:52
PHST- 2023/02/04 00:00 [received]
PHST- 2023/03/23 00:00 [accepted]
PHST- 2023/04/24 06:42 [medline]
PHST- 2023/04/24 06:41 [pubmed]
PHST- 2023/04/24 03:52 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1146108 [doi]
PST - epublish
SO  - Front Oncol. 2023 Apr 5;13:1146108. doi: 10.3389/fonc.2023.1146108. eCollection 
      2023.